Indazole

Indazole

SCHEMBL2732978

N#Cc1ccc2[nH]nc(Br)c2c1.c1ccc2[nH]ncc2c1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 2/20 0.53
HSP90AA1 P07900 1/20 0.47
IDO1 P14902 1/20 0.47
CDK2 P24941 1/20 0.47
ABCB1 P08183 1/20 0.43
TRPA1 O75762 1/20 0.42
METAP2 P50579 3/20 0.40
NOS1 P29475 3/20 0.40
CSNK2A1 P68400 1/20 0.40
MAPK10 P53779 1/20 0.39
RIPK1 Q13546 1/20 0.39
DYRK1A Q13627 2/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
LRRK2 Q5S007 1/20 0.38
DYRK3 O43781 1/20 0.38
CLK1 P49759 1/20 0.38
CLK2 P49760 1/20 0.38
CLK3 P49761 1/20 0.38
GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5801247 0.91 NOS1 (0.46) ITKTRPA1METAP2NOS1CSNK2A1
SCHEMBL30548034 0.84 ITK (0.50) ITKMAPK10RIPK1LRRK2GSK3B
SCHEMBL2870356 0.84 ITK (0.50) ITKMAPK10RIPK1LRRK2GSK3B
SCHEMBL774832 0.74 TRPA1 (0.54) HSP90AA1IDO1CDK2TRPA1METAP2
SCHEMBL29740998 0.74 TRPA1 (0.54) HSP90AA1IDO1CDK2TRPA1METAP2
Hydrochloric Acid SCHEMBL5419653 0.73 TRPA1 (0.53) HSP90AA1IDO1CDK2TRPA1METAP2
SCHEMBL30548023 0.72 TTK (0.51) ITKTRPA1METAP2NOS1MAPK10
SCHEMBL11963314 0.72 TTK (0.51) ITKTRPA1METAP2NOS1MAPK10
SCHEMBL29941668 0.71 NOS1 (0.53) HSP90AA1IDO1CDK2METAP2NOS1
SCHEMBL578190 0.71 NOS1 (0.53) HSP90AA1IDO1CDK2METAP2NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3536319-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-09-11 EP disclosed
US-8999966-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2015-04-07 US disclosed
US-20130237518-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP 2013-09-12 US disclosed
EP-2632268-A2 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-09-04 EP disclosed
WO-2012058127-A2 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS SCHERING CORPORATION (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237518-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAP3K20 ITK 1945/4885HSP90AA1 1983/4885IDO1 3102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.